Currax Pharmaceuticals CEO, George Hampton discusses what patient success has looked like for their oral anti-obesity medication, how expanded access can help with the world's obesity epidemic, when prices should come down, and much more. 

In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands. 

Featured in this episode are:
Emma Banks, CEO, ramarketing
Jill Jaroch, Senior Director, Women’s Health & Urology Marketing, Astellas
Marie Teil, Global Head, UCB’s Women of Childbearing Age Program
Julia Lakeland, Chief Product Office, uMotif

If you enjoyed this episode of our podcast, we encourage you to seek out the longer version of each of these videos—Linked on our website! 

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses their recent data and research about some massive behavioral shifts occurring across Gen-Z, and how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract the ever elusive generation. 

Jingsong Wang, Chairman of Nona Biosciences, discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033, an innovative antibody-drug conjugate (ADC) targeting MSLN, a key antigen in various solid tumors. Wang believes that the partnership will significantly advance Nona's Harbour Mice® platform and ADC ecosystem.

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more. 

Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene, discusses findings from their new study about Reshaping Pharmacovigilance in the age of AI, digital/generative AI opportunities, how quickly the industry is adopting this technology, and much more.

Dr. Julien Boisdron, Global Head of OneMedical / Chief Medical Officer Roche Diabetes Care, discusses the current standard for diabetes care, the importance of patient advocacy and mental health, what the future of this space holds, and much more. 

Edward Triebell, Commercial Executive Director for MRN Technologies, discusses the biggest digital trends in clinical research right now, how COVID-19 impacted the use of digital within sponsors and CROs, what the future of DCT services looks like, and much more.

David Klein, co founder and CEO of Click Therapeutics, discusses the new FDA SaMD guidance, the clear differences between companion apps and SaMD, and gives insight into what to expect from this combination in the future.

In this exclusive Pharm Exec Podcast episode with Paul Biondi, executive partner at Flagship Pioneering (the venture creation firm behind Moderna and many other life science firms) and president of Pioneering Medicines, Meg Rivers, managing editor, asks Biondi about 1) the process of founding a company; 2) what factors they consider when deciding whether to partner with a pharmaceutical company (like your partnership with Novo Nordisk) or a foundation (like your partnership with the Cystic Fibrosis Foundation)—along with what makes one organization stand out from another; 3) where science is booming in pharma right now; 4) deciding whether to found a company looking to launch innovations in an existing space vs. pursue innovations in an untapped space; and 5) signs that a company will achieve commercial success from early on.

Commercialization is a tough road to navigate even for the most established bio/pharmaceutical therapies. But as cell and gene therapies (CGTs) continue to form roots and make a splash worldwide—but specifically in the US—commercialization forms its own version of standardization and best practices.
In this exclusive interview with Pharmaceutical Executive, Lung-I Cheng, vice president of CGT, Cencora (formerly AmerisourceBergen), discusses:
1) defining CGT commercialization strategies and foundational knowledge—and the best music metaphor
2) what he wishes companies knew about commercialization strategies
3) common knowledge gaps of CGTs
4) how CGT developers can overcome key challenges, including those related to patient access, regulatory requirements, and market access
5) how planning for allogeneic cell therapies differs from autologous cell therapies and gene therapies
6) how companies can demonstrate CGT value as more products enter the development pipeline (and competition intensifies)
7) when to start planning a CGT commercialization strategy
8) predictions for the CGT market in five years